Next Article in Journal
Enhanced Antioxidant and Cytotoxic Potentials of Lipopolysaccharides-Injected Musca domestica Larvae
Previous Article in Journal
Transferrin-Conjugated pH-Responsive γ-Cyclodextrin Nanoparticles for Antitumoral Topotecan Delivery
Previous Article in Special Issue
Nano-Vesicle Based Anti-Fungal Formulation Shows Higher Stability, Skin Diffusion, Biosafety and Anti-Fungal Efficacy In Vitro
Open AccessArticle

Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I

1
Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Humboldtstrasse 10, 07743 Jena, Germany
2
Jena Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, 07743 Jena, Germany
3
Department of Anesthesiology and Intensive Care Medicine, Nanophysiology Group, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany
4
Center for Sepsis Control and Care, Jena University Hospital, 07747 Jena, Germany
5
Institute of Pharmacy, Department of Pharmaceutical Technology and Biopharmacy, Friedrich Schiller University Jena, Lessingstrasse 8, 07743 Jena, Germany
6
SmartDyeLivery GmbH, Botzstrasse 5, 07743 Jena, Germany
*
Author to whom correspondence should be addressed.
Pharmaceutics 2020, 12(11), 1110; https://doi.org/10.3390/pharmaceutics12111110
Received: 3 October 2020 / Revised: 12 November 2020 / Accepted: 13 November 2020 / Published: 18 November 2020
(This article belongs to the Special Issue Drug Delivery by Soft Matter)
Bisindolylmaleimide I (BIM-I) is a competitive pan protein kinase C inhibitor with anti-inflammatory and anti-metastatic properties, suggested to treat inflammatory diseases and various cancer entities. However, despite its therapeutic potential, BIM-I has two major drawbacks, i.e., it has a poor water solubility, and it binds the human ether-à-go-go-related gene (hERG) ion channels, potentially causing deadly arrhythmias. In this case, a targeted delivery of BIM-I is imperative to minimize peripheral side effects. To circumvent these drawbacks BIM-I was encapsulated into nanoparticles prepared from poly(lactic-co-glycolic acid) (PLGA) functionalized by the near-infrared dye DY-635. DY-635 served as an active targeting moiety since it selectively binds the OATP1B1 and OATP1B3 transporters that are highly expressed in liver and cancer cells. PLGA-DY-635 (BIM-I) nanoparticles were produced by nanoprecipitation and characterized using dynamic light scattering, analytical ultracentrifugation, and cryogenic transmission electron microscopy. Particle sizes were found to be in the range of 20 to 70 nm, while a difference in sizes between the drug-loaded and unloaded particles was observed by all analytical techniques. In vitro studies demonstrated that PLGA-DY-635 (BIM-I) NPs prevent the PKC activation efficiently, proving the efficacy of the inhibitor after its encapsulation, and suggesting that BIM-I is released from the PLGA-NPs. Ultimately, our results present a feasible formulation strategy that improved the cytotoxicity profile of BIM-I and showed a high cellular uptake in the liver as demonstrated in vivo by intravital microscopy investigations. View Full-Text
Keywords: active targeting; bisindolylmaleimide I; drug delivery; liver disease; nanoparticle formulation; PKC; PLGA nanoparticles; theranostics active targeting; bisindolylmaleimide I; drug delivery; liver disease; nanoparticle formulation; PKC; PLGA nanoparticles; theranostics
Show Figures

Graphical abstract

MDPI and ACS Style

Shkodra, B.; Press, A.T.; Vollrath, A.; Nischang, I.; Schubert, S.; Hoeppener, S.; Haas, D.; Enzensperger, C.; Lehmann, M.; Babic, P.; Benecke, K.J.; Traeger, A.; Bauer, M.; Schubert, U.S. Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics 2020, 12, 1110. https://doi.org/10.3390/pharmaceutics12111110

AMA Style

Shkodra B, Press AT, Vollrath A, Nischang I, Schubert S, Hoeppener S, Haas D, Enzensperger C, Lehmann M, Babic P, Benecke KJ, Traeger A, Bauer M, Schubert US. Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I. Pharmaceutics. 2020; 12(11):1110. https://doi.org/10.3390/pharmaceutics12111110

Chicago/Turabian Style

Shkodra, Blerina; Press, Adrian T.; Vollrath, Antje; Nischang, Ivo; Schubert, Stephanie; Hoeppener, Stephanie; Haas, Dorothee; Enzensperger, Christoph; Lehmann, Marc; Babic, Petra; Benecke, Kay J.; Traeger, Anja; Bauer, Michael; Schubert, Ulrich S. 2020. "Formulation of Liver-Specific PLGA-DY-635 Nanoparticles Loaded with the Protein Kinase C Inhibitor Bisindolylmaleimide I" Pharmaceutics 12, no. 11: 1110. https://doi.org/10.3390/pharmaceutics12111110

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop